ViroFend Therapeutics

We are pioneering the future of cancer treatment through the use of oncolytic virotherapy - a groundbreaking approach that harnesses viruses to target and eliminate cancer cells.

Our core innovation revolves around using Avian Paramyxovirus (APMV)-based therapy. This innovative virotherapy effectively creates a personalized vaccine right at the tumor site, eliminating the need for complex processing or customization.

With our therapeutic approach is expected that viruses stimulate each patient's immune system to create its own unique vaccine tailored to its specific tumor. This process activates T cells against tumor neoantigens without the need for prior identification, a significant advancement over traditional immunotherapies.

Moreover, our APMV therapy has demonstrated the ability to elicit systemic, long-lasting anti-tumor responses in murine models, offering protection against cancer recurrence and metastasis.

By harnessing the power of the body's own immune system in this targeted manner, Virofend Therapeutics is opening new frontiers in cancer treatment, offering hope for more effective, personalized, and durable therapeutic outcomes.